Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05671770

Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)

Conditions: Fabry Disease

Sex: All
Ages: 18 Years – N/A
Enrollment: 230
Sponsor: Sanofi

Summary

Primary objective:To estimate the prevalence of patients who are at high-risk for Fabry Disease (FD) in the Cleveland Clinic, Abu Dhabi (CCAD) United Arab Emirates (EMR) database from May 2016 to May 2022, according to the predictive algorithm (i.e., feasibility assessment eligibility criteria)Secondary objectives:To estimate the prevalence of FD among patients at high-risk for FD (i.e., among enrolled patients)To characterize the patient profile, overall and in Cohorts 1 and 2To describe the most common characteristics among positive FD patients and negative FD patients

Eligibility Criteria

Inclusion Criteria:Patients who were identified as high-risk for FD via the predictive algorithm per the feasibility assessmentPatients who have signed an informed consent formCohort 1 (chronic kidney disease)Adult male patient ≤60 years old or adult female patient of any ageHaving chronic kidney diseaseHaving proteinuriaHaving one or more of the following conditions:Neuralgia and neuritis, unspecifiedDisturbances in skin sensationAnhidrosis, andHypertrophic cardiomyopathy.Cohort 2 (hypertrophic cardiomyopathy)Adult male patient ≤50 years old or adult female patient of any ageHaving hypertrophic cardiomyopathyHaving one or more of the following conditions:transient cerebral ischemic attack,chronic kidney disease.Exclusion Criteria:Patients with an established diagnosis of FD.The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05671770). StuddyBuddy aggregates publicly available trial information.